Pilot Study: Use of the Saccadometer to Detect Characteristic Saccadic Peak Velocity in Myasthenia Gravis Patients
NCT ID: NCT06501794
Last Updated: 2024-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2016-03-31
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Saccadic properties of a small group of patients with a confirmed diagnosis of MG will be measured to identify if characteristic hyperfast saccades are present.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myasthenia Gravis
Participants with a confirmed diagnosis of Myasthenia Gravis
Quantitative measurement of eye movements
Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quantitative measurement of eye movements
Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of Myasthenia Gravis by either a positive acetylcholine antibody serum test (AChR) and/or a positive single fibre electromyograph (SFEMG) test.
* Patient participants must have also had at least one episode of diplopia and/or eye movement abnormality attributed to their diagnosis of MG.
Healthy participants:
* Must have no history of eye movement abnormality
* No have no history of other auto-immune disease (specifically diabetes, Thyroid Eye Disease and Chronic External Ophthalmoplegia).
Exclusion Criteria
* Patients with confirmed Myasthenia Gravis who have not had at least one episode of diplopia and or ptosis.
* Patients with current or previous episodes of ocular motility dysfunction that have a confirmed diagnosis other than Myasthenia Gravis.
* Any healthy participant found to have an abnormality of vision or eye movement upon screening or a history of auto-immune disease.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Liverpool University Hospitals NHS Foundation Trust
OTHER_GOV
University of Liverpool
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Craig Murray, MRes
Role: PRINCIPAL_INVESTIGATOR
University of Liverpool
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UoL001162
Identifier Type: -
Identifier Source: org_study_id